Becton Dickinson (NYSE:BDX) sells basic healthcare products such as needles, surgical tools and syringes. It also sells products that are used in drug discovery and related lab functions. Sales aren't growing rapidly, but management has been able to control costs to boost earnings in the double digits annually. Going forward, investors should expect more than the same, and the stock looks very reasonably valued currently.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Recent Developments
Becton held an analyst day last fall, where it revealed details on its expected business trends over the next few years. The company sees growth in emerging markets, through the introduction of new products, and from acquisitions. It also plans to continue to cut costs and improve its cost structure through initiatives such as making its supply chain more efficient. On the new product front, it has continually reinvested sales into research and development. R&D expense is projected to triple to 18% by fiscal 2014 from 2009 levels of 6%.

The company's recent history suggests it should be able to continue to deliver on its goals. Since 2004, profit margins have steadily improved. Operating margins have increased from around 15% to above 20% over the last twelve months. Sales growth has been somewhat modest at 6.1% over the past five years, but the cost controls have allowed it to leverage this into annual profit growth close to 14%.

SEE: A Look At Corporate Profit Margins

Outlook and Valuation
For all of 2012, analysts project modest sales growth of 1.8% and total sales just below $8 billion. The current projections are for 2013 top-line growth of 3.6% and total sales of nearly $8.3 billion. Profit projections for these two annual periods are $5.70 and $6.19, respectively, and represent forward earnings multiples of 12.8 times and 11.8 times, respectively. This is well below Becton's five-year average of 16.4 and below the forward market multiple of 12.9.

The Bottom Line
Becton's rivals include CR Bard (NYSE:BCR), Baxter International (NYSE:BAX), CareFusion (NYSE:CFN) and PerkinElmer (NYSE:PKI). Only Baxter trades at a lower forward multiple for the coming year but has had some safety issues with some of its products. All over a high degree of sales stability, but Becton stands out for having one of the clearest growth strategies in the field as well as a solid track record of delivering on its goals.

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    8 Solid Utility Stocks for a Bear Market

    If you're seeking modest appreciation, generous dividend payments and resiliency, consider these eight utility stocks.
  2. Stock Analysis

    Why Phillips 66 (PSX) is a Solid Long-Term Bet

    Here's why Phillips 66 will likely remain one of the world’s largest and most profitable companies for a long time to come.
  3. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  4. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  5. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  6. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  7. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  8. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  9. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  10. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!